AGM Statement

11 June 2015

Source BioScience plc

('Source BioScience', the 'Group')

ANNUAL GENERAL MEETING STATEMENT

Laurie Turnbull, Chairman of Source BioScience, will be making the following comments at the 2015 Annual General Meeting to be held today at 10.30am:

 "Since our last Annual General Meeting, the Company has delivered another year of significant progress. Following the successful integration of the acquisitions made during 2013, we have completed a number of significant infrastructure projects to improve operational efficiencies and enhance capacity to meet the growing demand for the Group's services and products.

From a financial perspective 2014 was also another year of improvement, demonstrated by the key performance indicators of operating profit and EBITDA. The momentum created during 2014 has continued into 2015 and the Group continues to trade in line with management expectations for the full year.

Diagnostic services and products for healthcare

Source BioScience's capabilities in gene-based analysis, and the increasing demand from the NHS for gene-based diagnostics and companion diagnostics, has been a driver of growth for Diagnostics over recent years. The migration of our genomics capability into other diagnostic and predictive testing applications is an important strategy for continuing growth.

During June, Source BioScience has launched its non-invasive prenatal testing ('NIPT') service which can identify fragments of foetal DNA in maternal blood. NIPT significantly reduces the need for invasive procedures, such as amniocentesis, which are currently used to screen for genetic abnormalities and which present a potential risk of miscarriage.

Diagnostics activities continue to perform strongly and Sexually Transmitted Infection ('STI') testing is becoming an increasingly significant component of the portfolio. A number of additional Chlamydia screening contracts were awarded to the Group during 2014 under the National Chlamydia Screening Programme and during the first half of 2015 we have been engaged for a number of sexual health screening initiatives.

The Diagnostics product portfolio includes cytology for cervical cancer screening and serology for blood analysis and transplant applications. The landscape for cervical cancer screening continues to evolve as HPV testing becomes more widely adopted and compliance with the screening programme declines. At the same time, the Group continues to benefit from the investment which has been made in high throughput, high capacity serology production capability and "Class A" clean room facilities in Rochdale.

Sequencing services and products for life science research

Source BioScience continues to further its position as a leading provider of DNA sequencing, with the Overnight Service™ powering the growth of this element of our business. During 2014 we commissioned additional sequencing facilities in Los Angeles, BioCity Scotland and Tramore, Ireland.

In the first half of 2015 the Group has further expanded the sequencing laboratory network with the launch of the Overnight Service™ from our facility in Atlanta. This brings access to our rapid sequencing service into the reach of a number of significant centres for life sciences research on the east coast of the US.

Enhancements made to the website and web-based portal, are providing superior e-commerce and eShop solutions for our customers, enabling the geographical expansion of the products business. During 2014 product distribution commenced from our molecular biology laboratory in Atlanta, supporting our expansion into the US market. In 2015 we have increased our commercial resource with the recruitment of additional sales specialists in the US and the expansion of our UK-based telesales and technical support team.

Stability and biostorage services and products

Stability and biostorage services comprise stability storage, sample archiving and downstream laboratory analyses for customers in the biopharma, life sciences research and pharmaceutical contract manufacturing markets. Accreditation by relevant authorities is essential in providing services to these highly regulated markets. The Group's stability and biostorage activities are delivered from five sites in Nottingham, Rochdale, Tramore, Atlanta and Los Angeles.

To meet customer demand, the Group made significant capital investment in additional, specialised facilities in the UK and the US during 2014. As expected, our ability to provide a single site solution for storage and downstream analysis is attracting new customers. The performance of both the stability and biostorage activities has exceeded expectations during the early part of 2015 as the number of contracts continues to increase.

The Group also has a number of significant opportunities for the manufacture and supply of its high quality, standard and bespoke controlled environment walk-in room systems. These opportunities are for both installations on customer sites and in Source BioScience facilities to provide an enhanced, outsourced service solution. A number of substantial contracts are already underway and there is strong pipeline with new and existing customers. One of these bespoke projects has necessitated the design, specification and manufacture of chambers not currently available from any other supplier worldwide.

Outlook

Results for the year ended 31 December 2014 demonstrated another year of strong growth and progression for the business and trading for the early part of 2015 continues to build on the robust operational performance of the Group.

We look forward to updating shareholders further following the publication of our Half Year Report for the six months ending 30 June 2015, which we expect to release in August 2015."

--- ENDS ---

For further information, please contact:

Source BioScience plc

Dr Nick Ash, CEO

Tel: +44 (0) 115 973 9010

www.sourcebioscience.com

For investor enquiries:

N+1 Singer (Financial Advisor, Sponsor and Broker)

Aubrey Powell/James White

Tel: +44 (0)203 496 3000

www.nplus1singer.com

About Source BioScience

Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating nine state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.